About Bionano Genomics Inc
Ticker
info
BNGO
Trading on
info
NASDAQ
ISIN
info
US09075F3055
Industry
info
Medical Instruments & Supplies
Sector
info
Healthcare
CEO
info
Dr. Robert Erik Holmlin M.B.A., Ph.D.
Headquarters
info
9540 Towne Centre Drive, San Diego, CA, United States, 92121
Employees
info
344
Website
info
bionano.com
Bionano Genomics, Inc. provides genome analysis software that enables genomics labs to analyze and interpret data across a range of platforms to generate informative data visualizations for streamlined and simple reporting of causal variants. It offers Saphyr, a sample-to-result solution for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr instrument, a single-molecule imager; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; and Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight DNA. The company also provides Saphyr and Bionano compute servers; and VIA software, which offers one system for analysis and interpretation of genomic variants from microarray and next-generation sequencing data for cytogenetics and molecular genetics. In addition, it offers testing and laboratory services comprising FirstStepDx PLUS, a chromosomal microarray for identifying an underlying genetic cause in individuals with autism spectrum disorder, developmental delay, and intellectual disability; Fragile X syndrome (FXS) testing services; NextStepDx PLUS, a exome sequencing test to identify genetic variants that are associated with disorders of childhood development; OGM-Dx HemeOne testing; OGM-Dx FSHD, a test for individuals suspected of having FSHD type 1; and OGM-Dx Postnatal Whole Genome SV and OGM-Dx Prenatal Whole Genome SV for comprehensive testing. Bionano Genomics, Inc. was founded in 2003 and is headquartered in San Diego, California.
Metrics
BasicAdvanced
Market cap
info
$11.2M
P/E ratio
info
-
EPS
info
-$138.00
Dividend Yield
info
0.00%
Beta
info
2.25
Forward P/E ratio
info
0
EBIDTA
info
$-89.1M
Ex dividend date
info
-
Price & volume
Market cap
info
$11.2M
Average daily volume
info
0.1M
90-day return
info
-
30-day return
info
-
7-day return
info
-
Dividends
Dividend per share
info
$0.00
Dividend yield
info
0.00%
Forward dividend per share
info
$0.00
Forward dividend yield
info
0.00%
Payout ratio
info
0.00%
Valuation
P/E ratio
info
0
Forward P/E
info
0
PEG ratio
info
-
Trailing P/E
info
0
Price to sales
info
0.34
Price to book
info
0.22
Earnings
EPS
info
-$138.00
EPS estimate (current quarter)
info
-$0.21
EPS estimate (next quarter)
info
-$0.15
EBITDA
info
$-89.1M
Revenues (TTM)
info
$33.3M
Revenues per share (TTM)
info
$32.51
Technicals
Beta
info
2.25
52-week High
info
$75.60
52-week Low
info
$3.73
50-day moving average
info
$9.00
200-day moving average
info
$25.44
Short ratio
info
1.68
Short %
info
20.22%
Management effectiveness
ROE (TTM)
info
161.77%
ROA (TTM)
info
48.42%
Profit margin
info
0.00%
Gross profit margin
info
$-0.6M
Operating margin
info
372.58%
Growth
Quarterly earnings growth (YoY)
info
0.00%
Quarterly revenue growth (YoY)
info
34.80%
Share stats
Outstanding Shares
info
2.7M
Float
info
1.5M
Insiders %
info
0.12%
Institutions %
info
10.26%
Analyst Insights & forecasts
info

0% Buy

100% Hold

0% Sell

Based on information from 3 analysts.

Average price target

info
$60.00
Earnings per share (EPS) forecast
windowbar_chart_4_bars
Actual
info
Expected
info
Surprise
info
-$0.96
-$0.87
10.26%
Q4 • 23Beat
-$0.51
-$0.64
20.31%
Q1 • 24Beat
-$0.22
-$0.42
47.62%
Q2 • 24Beat
-$0.27
-$0.21
27.38%
Q3 • 24Beat
-
-
-
Q4 • 24Current
QuarterlyAnnual
Financial Performance
windowbar_chart_4_bars
Income StatementBalance SheetCash Flow
windowbar_chart_4_bars
Revenue
info
Net income
info
Profit margin
info
$7.8M
$-16.2M
208.78%
Q2 • 24
$6.1M
$-44.2M
728.57%
Q3 • 24
21.85%
172.72%
248.97%
QoQ growth
QuarterlyAnnual
Totals assets
info
Total liabilities
info
Debt to assets
info
$129M
$49M
37.90%
Q2 • 24
$87.4M
$38.5M
44.06%
Q3 • 24
32.47%
21.48%
16.26%
QoQ growth
QuarterlyAnnual
Operating
info
Investing
info
Financing
info
Free cash flow
info
$-21M
$28.6M
$-2M
$-21.1M
Q2 • 24
$-13.3M
$-5.4M
$6M
$-13.3M
Q3 • 24
36.56%
118.77%
404.40%
36.79%
QoQ growth
QuarterlyAnnual

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Past performance is no guarantee of future results. Your return may be affected by currency fluctuations and applicable fees and charges. The value of your investment may go up as well as down. When investing, your capital at risk.

Build your future fund today!

Automate your wealth-building journey and turn investing into a habit that your future self will be grateful for!

Capital at risk.

FAQs

How much is a Bionano Genomics Inc share?
Collapse

Bionano Genomics Inc shares are currently traded for undefined per share.

How many shares does Bionano Genomics Inc have?
Collapse

Bionano Genomics Inc currently has 2.7M shares.

Does Bionano Genomics Inc pay dividends?
Collapse

No, Bionano Genomics Inc doesn't pay dividends.

What is Bionano Genomics Inc 52 week high?
Collapse

Bionano Genomics Inc 52 week high is $75.60.

What is Bionano Genomics Inc 52 week low?
Collapse

Bionano Genomics Inc 52 week low is $3.73.

What is the 200-day moving average of Bionano Genomics Inc?
Collapse

Bionano Genomics Inc 200-day moving average is $25.44.

Who is Bionano Genomics Inc CEO?
Collapse

The CEO of Bionano Genomics Inc is Dr. Robert Erik Holmlin M.B.A., Ph.D..

How many employees Bionano Genomics Inc has?
Collapse

Bionano Genomics Inc has 344 employees.

What is the market cap of Bionano Genomics Inc?
Collapse

The market cap of Bionano Genomics Inc is $11.2M.

What is the P/E of Bionano Genomics Inc?
Collapse

The current P/E of Bionano Genomics Inc is null.

What is the EPS of Bionano Genomics Inc?
Collapse

The EPS of Bionano Genomics Inc is -$138.00.

What is the PEG Ratio of Bionano Genomics Inc?
Collapse

The PEG Ratio of Bionano Genomics Inc is null.

What do analysts say about Bionano Genomics Inc?
Collapse

According to the analysts Bionano Genomics Inc is considered a hold.